论文部分内容阅读
目的探讨干扰素抗病毒治疗对慢性乙型肝炎(CHB)患者外周血单个核细胞(PBMCs)端粒酶逆转录酶活性表达的影响。方法用淋巴细胞分离液分离37例干扰素治疗CHB患者(干扰素治疗组),36例CHB对照患者(患者对照组)和10例健康人(健康对照组)的PBMCs,用Real-time RT-PCR方法定量检测各组PBMCs表达的hTERT mRNA及其相应β-actin mRNA,计算出标化的hTERT mRNA(NhTERT mRNA)。结果干扰素治疗12个月时,治疗组PBMCs表达NhTERT mRNA的水平与正常对照组之间无统计学差异,但两组均显著高于患者对照组(P<0.001;P=0.001)。hTERT mRNA的水平与研究对象的年龄、患者基线ALT水平、HBV DNA载量及病毒基因型等均未见显著相关性关系(均为P>0.05),但治疗12个月时,其水平与同期检测的CD3+T淋巴细胞计数、CD4+/CD8+比值均呈显著正相关关系(P<0.05)。并且发现,在干扰素治疗组中NhTERT mRNA的表达随治疗时间的延长而显著增加,在治疗12个月时获得完全应答的患者组NhTERT mRNA水平显著高于无应答组(P<0.05)。结论 CHB患者PBMCs端粒酶活性表达低下,干扰素抗病毒治疗可以上调患者淋巴细胞端粒酶活性,这可能是干扰素促进患者免疫功能恢复的一种机制。
Objective To investigate the effect of interferon antiviral therapy on the expression of telomerase reverse transcriptase in peripheral blood mononuclear cells (PBMCs) from patients with chronic hepatitis B (CHB). Methods Thirty-seven PBMCs from CHB patients (interferon treated group), 36 CHB control patients (control group) and 10 healthy people (healthy control group) were separated by lymphocyte separation liquid. Real-time RT- PCR method was used to quantitatively detect hTERT mRNA and its corresponding β-actin mRNA expressed in PBMCs of each group, and the normalized hTERT mRNA (NhTERT mRNA) was calculated. Results The level of NhTERT mRNA expression in PBMCs in the treatment group was not significantly different from that in the normal control group at 12 months after treatment with interferon, but both groups were significantly higher than the control group (P <0.001; P = 0.001). There was no significant correlation between the level of hTERT mRNA and age of patients, baseline ALT level, HBV DNA load and virus genotype (all P> 0.05). However, the level of hTERT mRNA at the same time There were significant positive correlations between CD3 + T lymphocyte count and CD4 + / CD8 + ratio (P <0.05). And found that in the interferon treatment group NhTERT mRNA expression increased significantly with the extension of treatment time, at 12 months after treatment in patients with complete response NhTERT mRNA levels were significantly higher than those without response (P <0.05). Conclusion The expression of telomerase activity in PBMCs of CHB patients is low. Interferon antiviral therapy can increase telomerase activity of lymphocytes in patients with CHB, which may be a mechanism by which interferon can promote the recovery of immune function in patients.